Remove prioritizing-lower-priced-biosimilar-medications
article thumbnail

Agile, Data-Driven Life Cycle Management for Continuous Manufacturing

ISPE

1 , 2 The FDA has been prioritizing advanced manufacturing and adding staff to its Emerging Technology platform, but regulation expectations from other markets (e.g., Generics and Biosimilars Initiative Journal 10, no. China and Brazil) can add resistance to approvals. Siang, and C. 1 (March 2021):44–56. doi:10.5639/gabij.2021.1001.004